Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Haleon Shares Rise After GSK, Pfizer Indeminification Requests Rejected

Published 09/20/2022, 03:48 AM
Updated 09/20/2022, 03:52 AM
GSK
-
PFE
-
HLN
-

By Scott Kanowsky 

Investing.com -- Shares in HALEON PLC (LON:HLN) edged higher after the consumer healthcare firm rejected requests for indemnification from GSK (LON:GSK) and Pfizer (NYSE:PFE) over litigation in the U.S. related to the heartburn drug, Zantac.

In a statement, the U.K's Haleon - a spin-off comprised of assets previously owned by GSK and Pfizer - repeated its assertion made earlier this year that it was "not a party" to any claims made against Zantac.

"[T]he scope of the indemnities set out in the joint venture agreement only covers their consumer healthcare businesses as conducted when the JV was formed in 2018. At that time, neither GSK nor Pfizer marketed OTC Zantac in the US or Canada," Haleon said.

The business previously warned of risks stemming from the Zantac lawsuits in its prospectus ahead of its listing in July.

More than 2,000 personal injury cases purporting a connection between Zantac and cancer have been filed, with claimants accusing - among others - GSK and Pfizer of not adequately warning customers.

GSK has said that in-house research, as well as studies from the U.S. Food & Drug Administration and the European Medicines Agency, have all found no evidence of a causal link between ranitidine - the active ingredient in Zantac - and the development of cancer in patients.

Elsewhere on Tuesday, Haleon posted a 22.1% jump in first-half adjusted operating profit, as the maker of Sensodyne toothpaste and Advil painkillers was boosted by increased demand from households and geographic expansion. Over the six-month period, two-thirds of the firm's business gained or maintained market share, it said.

The group added that third quarter trading momentum was "positive," but will slow due to challenges posed by the impact of soaring inflation on consumer spending.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.